Press releases

  • Translational biomedical engineering: Intelligent inhalation system / 2018

    Gentle treatment for premature babies with lung diseases

    Press release / 10.12.2018

    Premature babies who are born before their lungs have finished maturing often suffer from a lack of surfactant – a substance necessary for lung development. They are also particularly susceptible to illnesses of the respiratory organ, which have to be treated by means of inhalation. However, the inhalation systems available are not geared to the needs of preterm infants and newborns. Researchers at the Fraunhofer Institute for Toxicology and Experimental Medicine ITEM are working with partners to develop a system that would allow drugs to be administered as aerosols in an efficient and breath-triggered manner. This would shorten therapy duration, thereby easing the strain on little bodies.

    more info
  • On November 8, 2018, 16 Australian researchers visited Fraunhofer ITEM as part of the InnoTour 2018. In addition to lectures on the “Integration of Human Tissue for Research and Development”, the guests were offered guided tours through the clinical research center CRC Hannover, which gave the Australian visitors an insight into the state of the art of in-vitro toxicology and ex-vivo methods.

    more info
  • MEDICA/COMPAMED 2018 / 2018

    No chance for bacteria on implants


    Hip and dental implant operations are routine. But not entirely risk-free. They may result in infection that is difficult to control with oral or intravenous antibiotics. In such cases, the implant will probably need to be replaced. Fraunhofer researchers can now apply a precisely matched drug directly to the replacement implant while significantly increasing the effectiveness of the antibiotic via a synergism with silver ions. Their research will be on display at the MEDICA and COMPAMED trade fairs in Düsseldorf from November 12 to 15, 2018 (Hall 8a, Booth P13).

    more info
  • Patient safety is top priority in medicine and biomedical engineering. Aiming to increase patient safety, the EU introduced the European Medical Device Regulation (MDR) in 2017. Representatives of the medtech sector are expecting massive negative consequences from the regulation and are suggesting specific measures for a revision of the MDR.

    more info
  • Innovative approaches to metastasis research / 2018

    Fraunhofer researcher Prof. Christoph Klein received the “Fidler Innovation Award”


    Researcher Prof. Christoph Klein, Fraunhofer ITEM Division Director of Personalized Tumor Therapy and Senior Professor of Experimental Medicine and Therapy Research at the University of Regensburg (Germany) has been given the international “I.J. ‘Josh‘ Fidler Innovation in Metastasis Research Award”. Prof. Klein received this award for his innovative contributions to metastasis research. The award ceremony took place in Princeton, USA, on August 3, 2018, during the 17th Congress of the Metastasis Research Society.

    more info
  • In the development of new medications and medical engineering, there is a gap between the discovery of new potential active ingredients and products and their further development into medicinal products and medical devices by the industry. The Helmholtz Association and the Fraunhofer-Gesellschaft, together with the Deutsche Hochschulmedizin, have now jointly brought the Proof-of-Concept initiative into being. It promotes the translation of innovative, promising research projects.

    more info
  • Battling infection and resistance / 2018

    Fraunhofer launches German-Australian iCAIR project


    A pioneering collaboration of three partners – Fraunhofer ITEM, the Hannover Medical School (MHH), and Griffith University’s Institute for Glycomics (IfG) in Gold Coast, Australia – was officially launched on January 18, 2018. The aim of the collaborative project iCAIR is to develop new anti-infective drugs.

    more info
  • Bacteriophages join the fight against infection / 2017

    Research alliance launched, aimed at establishing bacteriophages as an approved drug


    (Hannover, Germany) Bacteria worldwide keep developing new resistances to antibiotics. Alternative therapies are urgently needed to meet this challenge. To this end, the Fraunhofer Institute for Toxicology and Experimental Medicine ITEM, Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures, Charité – Universitätsmedizin Berlin, and Charité Research Organisation have teamed up and initiated the project “Phage4Cure”. The goal is to establish bacteriophages as an approved drug for treating bacterial infections. The German Federal Ministry of Education and Research is funding this project with almost four million euros over a period of three years.

    more info